Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

19 May 2023

Abstract excerpt

Small molecule inhibitors targeting JAK2 provide symptomatic benefits for myeloproliferative neoplasm (MPN) patients and are among first-line therapeutic agents. However, despite all having potent capacity to suppress JAK-STAT signaling, they demonstrate distinct clinical profiles suggesting contributory effects in targeting other ancillary pathways. Here, we performed comprehensive profiling on four JAK2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37203407
DOI: 10.1002/ajh.26935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsPMID 37203407Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNSemantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.Semantic proximity Read ↗

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Semantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.